Inj, eculizumab-aagh, 2 mg
Products billed under this code include Epysqli.
Payment limit per 2 MG, by effective quarter, 1Q26 to 4Q26. Gaps mean the code was not in that quarter’s file, or CMS gave no payment limit.Products billed under this code include Epysqli.
Payment limit per 2 MG, by effective quarter, 1Q26 to 4Q26. Gaps mean the code was not in that quarter’s file, or CMS gave no payment limit.From the 4Q26 NDC–HCPCS crosswalk. “Limit / pkg” is the 4Q26 payment limit times the billing units in one package.
| Product | Labeler | NDC | Units / pkg | Limit / pkg |
|---|---|---|---|---|
| Epysqli | Nupathe Inc | 51759-0208-13 | 150 | $4,732.05 |
| Quarter | Payment limit | Change | Billing unit | Description | Source file |
|---|---|---|---|---|---|
| 4Q26 | $31.547 | −$0.22 | 2 MG | Inj, eculizumab-aagh, 2 mg | v1, posted September 17, 2026 |
| 3Q26 | $31.767 | −$0.161 | 2 MG | Inj, eculizumab-aagh, 2 mg | v1, posted September 15, 2026 |
| 2Q26 | $31.928 | +$0.256 | 2 MG | Inj, eculizumab-aagh, 2 mg | v1, posted September 15, 2026 |
| 1Q26 | $31.672 | – | 2 MG | Inj, eculizumab-aagh, 2 mg | v1, posted September 15, 2026 |
“Change” is the difference from the previous quarter, shown only when both quarters have a payment limit and the billing unit is the same. “vs. last quarter” and “vs. a year ago” follow the same rule.